Product Specifications:
Item # 2500: Human Anti HIV-1 pAb IgG
Concentration: See vial
Mass/vial: 100ug
Diluent: PBS
Purity: >90%
Stabilizer: None
Preservative: None
Storage: -75°C
Physical State: Frozen Liquid
Stability: At least 6 months at -75°C
Minimum Dilution: 1 : 1000
Application: ELISA/gp120 Western ELISA, Immunoprecipitation, Immunohistochemistry, Virus Neutralization Assays, FACS, gp120 Capture ELISA.
Description: Protein A/G affinity purified pAb IgG fraction from HIV-1 immune human serum .
Purification: This pAb IgG was purified by proteinA/G affinity chromatography to >95% purity as determined by SDS-PAGE, reduced.
Specificity: This pAb IgG binds to native and recombinant HIV-1viral protein lysates as determined by ELISA and Component HIV-1 envelope, core and regulatory proteins as determined by Western ELISA.
Biological Activity: Neutralizes HIV-1 virus in co-cultures as assayed by syncycium formation and in supT1 infected cells by p24, RT, LTR-CAT activation and cell viability assays.
Application and Instructions for use:
Recommended dilutions for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. This pAb IgG yields titres of greater than 1 : 2000 with 100ng of immobilized gp120/160 (IDI Product# 1001, 1004) under standard conditions. ELISA and Western ELISA may be performed at 1-5µg/ml of pAb depending on the nature and the quantity of the immobilized antigen. Histochemical studies require dilutions in 1 : 200 dilution range. Virus neutralization assays may be performed in 0.1 to 10µg/ml range.
Caution: This product is dervived from HIV-1 infected, converted human serum. Use of needles for handling and transfer of this product is not recommended. This product must be used by trained professional only, following all the necessary bio-safety precautions and procedures.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.
)懂得一些道理或知识.
让世界充满爱不仅是付出,还可以是回报,回报你所关爱的人.
我记得有首歌曲,它的意思是爸爸妈妈辛苦了一天,回到家,帮他们拿拖鞋,帮他们倒杯茶,这是感
恩.老师批改作业累了,可以给他们捶捶背,当学习获得了一定的成功,老师会感到欣慰,这是感恩.当
同学遭遇困难时,你可以去用尽全力地安慰帮助他(她),使他(她)能够解决困难,克服困难,变得快
乐.这也是感恩.
为了帮助临床医师客观地了解NSAIDs,避开制药公司的导向以便更好地指导临床实践,本报请广州中山大学附属第一医院风湿免疫内科杨岫岩教授向读者介绍NSAIDs临床应用的一些问题。
NSAIDs的发展
从乙酰水杨酸(阿司匹林)应用至临床到现在,已经超过100个年头。1948年第一个非水杨酸类的NSAIDs保泰松问世后,抗炎镇痛药的种类迅速增加,如吲哚美辛、双氯芬酸、布洛芬、萘普生等,使NSAIDs“家族”迅速壮大。作为其“元老”的保泰松,虽然具有很强的抗炎镇痛作用,但潜在的严重副作用(再生障碍性贫血等)使其被淘汰。
1971年,环氧化酶(COX)理论解释了NSAIDs的作用机制。NSAIDs通过抑制COX,阻止花生四烯酸转变为前列腺素,后者既是炎症介质,又有生理功能。因此NSAIDs在抗炎镇痛的同时可引起胃肠道反应。20年后,研究者发现,COX存在不同的异构体,从而提出了COX异构体理论。认为COX存在两个异构体,一个是构建型的,称COX-1,以维持生理平衡为主;另一个是诱导型的称COX-2,主要参与炎症性前列腺素合成。
1994年,氟舒胺成为第一个被报道在实验室证实具有选择性COX-2抑制作用的NSAIDs,但在1996年III期临床试验总结时发现,该药具有肝毒性而未能获准上市。1995年Lancet上首先称萘丁美酮、美洛昔康、尼美舒利等为“选择性COX-2抑制剂”,虽然同年该期刊刊出几篇读者来信,对此提法提出争议,但是后来人们仍普遍接受这种提法。1999年,针对COX异构体理论研制的昔布类药物(塞来昔布和罗非昔布)上市,被称为“特异性COX-2抑制剂”。
虽然COX异构体理论尚需完善,但它的确是新型NSAIDs研制的一个突破口。除已经问世的昔布类药物外,新的昔布类Etoricoxib、parecoxib、valdecoxib也将投入临床。新研制的COX-2抑制剂不只限于昔布类,磺酰苯胺类也是研制新型COX-2抑制剂的方向,如氟舒胺、NS-398、HN-56249等。另外,针对COX和脂氧化酶(5-lipoxygenase

